MAP3K1 Antibodies

Mitogen-activated protein kinase kinase kinase 1 (MAP3K1)

Component of a protein kinase signal transduction cascade (PubMed:9808624). Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4 (PubMed:9808624).

May phosphorylate the MAPK8/JNK1 kinase (PubMed:17761173). Activates CHUK and IKBKB, the fundamental protein kinases of the NF- kappa-B pathway (PubMed:9808624).

Gene Information

Human
Gene Name:	MAP3K1
Uniprot:	Q13233
Entrez:	4214

Family

Belongs to:
protein kinase superfamily

Alternative Names

Map3k1; MAPK/ERK kinase kinase 1; MAPKKK1MAP/ERK kinase kinase 1; MEK kinase 1; MEKK1EC 2.7.11.25; MEKKMEKK 1; mitogen-activated protein kinase kinase kinase 1

Molecular Weight

Mass (kDA):
164.47 kDA

Genomic Context

Human
Location:	5q11.2
Sequence:	5; NC_000005.10 (56815543..56896152)

Diseases

• Malignant Neoplasms
• Neoplasms
• Malignant Neoplasm Of Breast
• Mammary Neoplasms
• Cell Transformation, Neoplastic
• Carcinoma
• Tissue Adhesions
• Inflammation
• Leukemia
• Neoplasm Metastasis
• Tumor Angiogenesis
• Malignant Paraganglionic Neoplasm
• Cell Invasion

• Liver Carcinoma
• Pertussis
• Melanoma
• Growth Arrest
• Carcinogenesis
• Malignant Squamous Cell Neoplasm
• Pancreatic Neoplasm

Interacting Proteins

• ARRB2
• BRAF
• DCAF7
• FLNB
• MAP2K4

• MAP4K2
• TRAF2

Pathways

• Cell Death
• Cell Proliferation
• Cell Cycle
• Cell Growth
• Secretion
• Induction Of Apoptosis
• Angiogenesis
• Localization
• Cell Migration
• Pathogenesis
• Cell Differentiation
• Cell Adhesion
• Cell Cycle Arrest

• Mapk Cascade
• Chemotaxis
• Cell Activation
• Protein Phosphorylation
• Immune Response
• Proteolysis
• T Cell Activation

PTMs

• Phosphorylation
• Cleavage
• Ubiquitination
• Dephosphorylation
• Sumoylation

• Acetylation
• Nitrosylation
• Phosphorothioation
• Methylation
• Myristoylation

Research Areas

• Angiogenesis
• Breast Cancer
• Cancer
• Lipid and Metabolism
• MAP Kinase Signaling

• mTOR Pathway
• Protein Kinase
• Signal Transduction
• Tyrosine Kinases

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/MAP3K1

Boster Bio - Best Uses Of The MAP3K1 Marker

BosterBio is a tool that detects kidney injury. But is there any other uses for the MAP3K1 MAP3K1 indicator? These uses will be covered in this article, along with the explanation of the alias MEKK1.

Boster Bio

According to reports, the MEKK1 gene is a member of Mitogen-Activated Protein Kinase family (MAP3K). It is a member of the Protein kinase superfamily and subfamily of STE Ser/Thr kinases. This antibody has target specificity and designated applications. Continue reading to learn more about the benefits of this antibody, and how to use it in your laboratory.

MEKK1 is a reported alias name for MAP3K1

The human gene MAP3K1 has also been known as MEKK1. This protein belongs to the Mitogen-Activated Protein Kinase Kinases subfamily (MAP3Ks). It has many applications. Boster Bio has generated a series of antibodies against this protein.

MAP3K1 is a potential therapeutic target in kidney injury

MAP3Ks can be therapeutic targets for kidney injuries as they are upstream regulators intracellular signaling. The kinases MAP3K1 (and MAP3K4) are involved in many aspects related to kidney disease, including hypertension-induced kidney injury, diabetic nephropathy, hypertension, as well as hypertension-induced kidney damage. There is currently no evidence to support the therapeutic role of MAP3K1 for kidney injury. However, a few MAP3Ks were implicated in this process.

Recent research has identified a binding site between MAP3K1 & let-7g-5p. Let-7g-5p regulates MAP3K1. NEAT1 and MAP3K1 had a positive regulatory relationship. qRT-PCR also detected the expression of MAP3K1 as well as let-7g-5p from clinical samples.

567 patients suffering from mCRC were part of the study. The patients were tested in order to identify genetic alterations that activate PI3K/MAPK signaling. Potential therapeutic targets for MAP2K1 (ERBB2) were also identified. These results are consistent in clinical settings with those of other studies. However, future studies need to confirm this finding. This research can provide valuable data that could be used to develop new treatments for kidney injuries.

Transient expressions of MAP3K1 inhibit cell growth. MTDH and BAX proteins were reduced after transfection with MIR-145 and MIR-224 inhibitor. Similarly, MIR-375 reduced protein expression in kidney cells. In addition, the transient MAP3K1 expression also decreased the protein level. MAP3K1 was also less active than MTDH.